Nordic Life Science Days 2017: Super Session 7 – Transformative Oncology

Event Details

Advancing Cancer Immunotherapy by novel partnerships, bugs and bytes.

The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.

Place: Plenary Room – Main Hall, Malmömässan, Malmø, Sweden

The programme:


Topic / final titles to be confirmed


11:15 – 11:20

Introduction by Moderator

Benedicte Bakke, Senior Advisor, Int. Healthcare, Int. Corporate Division DNB

11:20 – 11:30

Cancer Immunotherapy: State-of the Art 2017

Khatereh Ahmadi, Executive Director, Oncology Search and Evaluation Lead, European Hub, MSD

11:30 – 11:40

Mono- and bispecific antibodies for tumor directed Immunotherapy

Per Norlen, CEO Alligator

11:40 – 11:55

The Future of Oncology – Gazing into the Crystal Ball

Stefan Ries, Global Head of External Innovation, Oncology Discovery, pRED, Roche

11:55 – 12:05

The Microbiome and Cancer immunotherapy

Christophe Bonny, CSO Enterome

12:05 – 12:15

Patient stratification and companion diagnostics – where are we heading?

Henrik Winther, Senior VP Precision Diagnostics, Immunovia AB

12:15 – 12:25

Machine learning / AI for patient stratification and neoantigen discovery

Richard Stratford, CEO OncoImmunity

12:25 – 12:30

Academic medical centers as partners for I-O innovation

Gary Sclar, VP Dana-Farber Innovations, Dana- Farber Cancer Inst.

12:30 – 12:35



Joint speaker lunch afterwards, details to follow.

For more information about the programme at NLS Days 2017, please visit the NLS Days webpage.


Print This Post